Zyversa Therapeutics Inc (ZVSA) Directors and Executive Officers

Officers & Directors

Gregory Frietag
Director

James Sapirstein
Director

Robert G. Finizio
Director

Peter Wolfe
Chief Financial Officer and Secretary

Min Chul Park, Ph.D.
Director

Peter Wolfe
Chief Financial Officer (Principal Financial and Accounting Officer)

Stephen C. Glover
Chief Executive Officer (Principal Executive Officer)

Stephen C. Glover
Chief Executive Officer, President and Chairman ,

Zyversa Therapeutics Inc currently has 6 employees.

News about Zyversa Therapeutics Inc Key Personnel

ZyVersa Therapeutics Charts Path Forward Amidst Financial Challenges with Promising Obesity Treatment

In a recent letter to shareholders, Stephen C. Glover, CEO of ZyVersa Therapeutics, detailed the company’s ambitious plans for the next nine months centered around its investigational treatment, the Inflammasome ASC Inhibitor IC 100. Glover expressed optimism that this innovative therapy, aimed at mitigating chronic inflammation associated with obesity, could not only combat the disease effectively but also alleviate a range of related comorbidities, thereby offering a multifaceted solution to a growing health crisis.Obesity remains a pressing issue worldwide, affecting millions and leading to a myriad of health complications, including cardiovascular diseases, diabetes, and certain forms of cancer. The in...

ZyVersa Therapeutics' Vision for 2024: Advancing the Boundaries of Renal and Inflammatory Disease Treatment

ZyVersa Therapeutics: Advancing Innovative Treatment for Renal and Inflammatory Diseases in 2024
WESTON, Fla., Jan. 03, 2024 - ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; ZyVersa), a prominent clinical-stage specialty biopharmaceutical company has released a much-anticipated corporate outlook for 2024. In a recent Letter to Shareholders, Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President of ZyVersa, outlined the company s vision for the upcoming year and highlighted key milestones.
ZyVersa Therapeutics has rapidly emerged as a frontrunner in the field of drug development, aiming to revolutionize the treatment landscape for patients suffering from renal and inflammatory dise...